Perlara
Perlara: building the YC for rare disease parents
Perlara 1.0 (Feb 2014 - Feb 2019) launched early R&D joint ventures called PerlQuests with highly motivated rare disease families, companies or impact investors. We screened gene-edited patient avatars for repurposable drugs in order to build a predictive R&D engine called ArkBase. We planned to monetize programs based on ArkBase predictions by selectively spinning out asset-centric clinical development NewCos. Perlara 1.5 (March 2019 - April 2020) was the transition to a one-person virtual clinical development company and when the epalrestat and aripiprazole repurposing trials were launched at Mayo Clinic for the treatment of PMM2-CDG and NGLY1-CDDG, respectively. Perlara 2.0 (May 2020 --> The first decentralized and distributed biotech
- Website
- perlara.com
- City
- San Francisco
- Country
- United States
- YC batch
- Winter 2016
- Team
- 1 people
- Stage
- Early stage
- AI-native
- No
More Health & bio in San Francisco
Innovaccer$1.3bn
Indian digital healthcare company.
Thatch$1bn
Health benefits. Valued at $1bn (September 2026).
Chan Zuckerberg BiohubLab
Nonprofit research network building virtual cell models.
AthelasHiring
Extensible, Integrated Technology that Simplifies Health Systems
ClipboardHiring
Every shift, Covered.
Benchling
Unlocking the power of biotech with modern software for modern science
Claim this profile
Free and instant: prove you run perlara.com and edit the profile yourself.
- Your logo, office address and founder photos
- The ✓ Verified mark next to Perlara across the site
- Open roles listed on the Hiring board
- A followed link back to your website
A rank card with Perlara's standing on Labspie, or a simple badge. Both link to this profile and update themselves.
